Kyung-Soo Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kyung-Soo Kim has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Cheol-Young Park
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
20 shared publications - Kyungdo Han
Soongsil University 5 Department of Statistics and Actuarial Science Seoul, Republic of Korea
8 shared publications - Sangmo Hong
Division of Endocrinology and Metabolism, Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea
8 shared publications Soo-Kyung Kim
Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine
7 shared publicationsYong-Wook Cho
Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine
7 shared publicationsKyungdo Han
Department of Statistics and Actuarial Science, Soongsil University (Han), Seoul 06978, Republic of Korea
6 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 25, 1488-1512
Metabolic dysfunction-associated steatotic liver disease: Pathogenesis, complications and pharmacological treatment
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing in prevalence worldwide. Pathogenesis of MASLD has been considerably heterogenous. Increased hepatic de novo lipogenesis, adipose tissue dysfunction, genetic predisposition, epigenetic mechanism, and other related factors have been associated with the development and progression of MASLD. Patients with MASLD are at high risk of not only adverse liver-related outcomes, including hepatocellular carcinoma, but also cardiometabolic disease including type 2 diabetes mellitus. Weight loss is the cornerstone of therapy among the various treatments for MASLD to decrease hepatic fat accumulation and delay the progression of inflammation and fibrosis. Resmetirom and semaglutide are approved for the treatment of metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis, and many drugs are under investigation. Careful attention should be paid to the screening of MASLD, and concerted efforts should be made to manage it appropriately.
- 22 September 2026
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 25, 1488-1512
Open AccessMetabolic dysfunction-associated steatotic liver disease: Pathogenesis, complications and pharmacological treatment
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing in prevalence worldwide. Pathogenesis of MASLD has been considerably heterogenous. Increased hepatic de novo lipogenesis, adipose tissue dysfunction, genetic predisposition, epigenetic mechanism, and other related factors have been associated with the development and progression of MASLD. Patients with MASLD are at high risk of not only adverse liver-related outcomes, including hepatocellular carcinoma, but also cardiometabolic disease including type 2 diabetes mellitus. Weight loss is the cornerstone of therapy among the various treatments for MASLD to decrease hepatic fat accumulation and delay the progression of inflammation and fibrosis. Resmetirom and semaglutide are approved for the treatment of metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis, and many drugs are under investigation. Careful attention should be paid to the screening of MASLD, and concerted efforts should be made to manage it appropriately.
- Open Access
- 7 September 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1901350
Effect of insulin sensitivity and secretion defects at mid-pregnancy on early postpartum glucose intolerance in women with gestational diabetes mellitus
Objective: This study aimed to evaluate how insulin sensitivity and secretion defects during mid-pregnancy influence the development of early postpartum glucose intolerance in women diagnosed with gestational diabetes mellitus (GDM). Methods: A total of 1,256 pregnant women diagnosed with GDM between October 2005 and March 2023 were enrolled. Participants were categorized into four groups: GDM-normal, GDM-secretion defect only, GDM-sensitivity defect only, and GDM-mixed defect. Postpartum glucose intolerance was defined as fasting plasma glucose ≥ 100 mg/dL or 2-h plasma glucose ≥ 140 mg/dL during a 75-g oral glucose tolerance test at 6–12 weeks after delivery. Results: Women presenting with a sensitivity defect at mid-pregnancy showed a significantly higher rate of postpartum glucose intolerance than those without sensitivity defect (64.9% vs. 46.6%, P < 0.001). Conversely, the presence of a secretion defect alone did not result in a significant difference. The highest prevalence of postpartum glucose intolerance was observed in patients with GDM-mixed defect (GDM-normal 45.7%, GDM-secretion defect only 48.5%, GDM-sensitivity defect only 62.8%, GDM-mixed defect 91.3%; P for trend < 0.001). The risk of postpartum glucose intolerance was 1.46 times higher (95% CI 1.07-2.00) for the GDM-sensitivity defect only group and 5.43 times higher (95% CI 1.20-24.56) for the GDM-mixed defect group, compared with the GDM-normal group. Conclusions: Among women with GDM, impaired insulin sensitivity identified at mid-pregnancy is associated with a substantially increased risk of early postpartum glucose intolerance, whereas insulin secretion defects are not significantly related to this risk.
- 7 September 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1901350
Open AccessEffect of insulin sensitivity and secretion defects at mid-pregnancy on early postpartum glucose intolerance in women with gestational diabetes mellitus
Objective: This study aimed to evaluate how insulin sensitivity and secretion defects during mid-pregnancy influence the development of early postpartum glucose intolerance in women diagnosed with gestational diabetes mellitus (GDM). Methods: A total of 1,256 pregnant women diagnosed with GDM between October 2005 and March 2023 were enrolled. Participants were categorized into four groups: GDM-normal, GDM-secretion defect only, GDM-sensitivity defect only, and GDM-mixed defect. Postpartum glucose intolerance was defined as fasting plasma glucose ≥ 100 mg/dL or 2-h plasma glucose ≥ 140 mg/dL during a 75-g oral glucose tolerance test at 6–12 weeks after delivery. Results: Women presenting with a sensitivity defect at mid-pregnancy showed a significantly higher rate of postpartum glucose intolerance than those without sensitivity defect (64.9% vs. 46.6%, P < 0.001). Conversely, the presence of a secretion defect alone did not result in a significant difference. The highest prevalence of postpartum glucose intolerance was observed in patients with GDM-mixed defect (GDM-normal 45.7%, GDM-secretion defect only 48.5%, GDM-sensitivity defect only 62.8%, GDM-mixed defect 91.3%; P for trend < 0.001). The risk of postpartum glucose intolerance was 1.46 times higher (95% CI 1.07-2.00) for the GDM-sensitivity defect only group and 5.43 times higher (95% CI 1.20-24.56) for the GDM-mixed defect group, compared with the GDM-normal group. Conclusions: Among women with GDM, impaired insulin sensitivity identified at mid-pregnancy is associated with a substantially increased risk of early postpartum glucose intolerance, whereas insulin secretion defects are not significantly related to this risk.
- Open Access
- 30 May 2026
- Published by Korean Thyroid Association in International Journal of Thyroidology
- Vol. 19 (1) , 60-67
The Starting Dosage of Levothyroxine for Hypothyroidism during Pregnancy
Hyunju Park, Arim Choi, Kyung-Soo Kim, Soo-Kyung Kim and Yong-Wook Cho. Int J Thyroidol 2026;19:60-7. https://doi.org/10.11106/ijt.2026.19.1.60
- 30 May 2026
- Published by Korean Thyroid Association in International Journal of Thyroidology
- Vol. 19 (1) , 60-67
Open AccessThe Starting Dosage of Levothyroxine for Hypothyroidism during Pregnancy
Hyunju Park, Arim Choi, Kyung-Soo Kim, Soo-Kyung Kim and Yong-Wook Cho. Int J Thyroidol 2026;19:60-7. https://doi.org/10.11106/ijt.2026.19.1.60
- Open Access
- 21 May 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1801839
Association between steatotic liver disease subtype and thyroid cancer in women: A nationwide population-based cohort study
Objective: This study aimed to investigate association between steatotic liver disease (SLD) subtype and thyroid cancer in women using a nationwide population-based cohort. Methods: This nationwide population-based cohort study included 2,089,609 women aged more than 40 years who participated in the 2009 health screening program and were followed up until 2022. Participants were divided into four groups based on their SLD status: no SLD, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-related liver disease (MetALD), and alcohol-related liver disease (ALD). Results: During a mean follow-up of 12.27 years, 40,072 (1.92%) women were newly diagnosed with thyroid cancer. Compared with the no SLD group, women with MASLD had a higher risk of thyroid cancer (hazard ratio [HR]: 1.19, 95% confidence interval [CI]: 1.16-1.22), whereas those with MetALD and ALD did not have a higher risk. The risk of thyroid cancer was higher in women with MASLD, including both premenopausal (HR: 1.21, 95% CI: 1.16-1.26) and postmenopausal women (HR: 1.17, 95% CI: 1.14-1.21). Women in the MetALD group showed no risk elevation of thyroid cancer regardless of their menopausal status. Postmenopausal women in the ALD group had a higher risk of thyroid cancer than those in the no SLD group (HR: 1.31, 95% CI: 1.05-1.64), whereas premenopausal women did not have a higher risk. Conclusions: Thyroid cancer risk was modestly increased in women with MASLD, whereas no significant associations were observed for MetALD or ALD.
- 21 May 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1801839
Open AccessAssociation between steatotic liver disease subtype and thyroid cancer in women: A nationwide population-based cohort study
Objective: This study aimed to investigate association between steatotic liver disease (SLD) subtype and thyroid cancer in women using a nationwide population-based cohort. Methods: This nationwide population-based cohort study included 2,089,609 women aged more than 40 years who participated in the 2009 health screening program and were followed up until 2022. Participants were divided into four groups based on their SLD status: no SLD, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-related liver disease (MetALD), and alcohol-related liver disease (ALD). Results: During a mean follow-up of 12.27 years, 40,072 (1.92%) women were newly diagnosed with thyroid cancer. Compared with the no SLD group, women with MASLD had a higher risk of thyroid cancer (hazard ratio [HR]: 1.19, 95% confidence interval [CI]: 1.16-1.22), whereas those with MetALD and ALD did not have a higher risk. The risk of thyroid cancer was higher in women with MASLD, including both premenopausal (HR: 1.21, 95% CI: 1.16-1.26) and postmenopausal women (HR: 1.17, 95% CI: 1.14-1.21). Women in the MetALD group showed no risk elevation of thyroid cancer regardless of their menopausal status. Postmenopausal women in the ALD group had a higher risk of thyroid cancer than those in the no SLD group (HR: 1.31, 95% CI: 1.05-1.64), whereas premenopausal women did not have a higher risk. Conclusions: Thyroid cancer risk was modestly increased in women with MASLD, whereas no significant associations were observed for MetALD or ALD.
- 5 May 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (7) , 1377-1386
Hypertriglyceridemia in adults with diabetes mellitus in Korea: Sex, age, and lifestyle determinants
- 5 May 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (7) , 1377-1386
Hypertriglyceridemia in adults with diabetes mellitus in Korea: Sex, age, and lifestyle determinants
- Open Access
- 28 February 2026
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 41 (1) , 26-33
Postpartum Glucose Intolerance in Women with a History of Gestational Diabetes Mellitus: An In-Depth Review
Gestational diabetes mellitus (GDM) is increasing in prevalence worldwide, and postpartum glucose intolerance represents one of the major complications after delivery in women with GDM. A wide range of risk factors for postpartum glucose intolerance have been identified, including ethnicity, genetic predisposition, age, obesity, pre-pregnancy body mass index, gestational weight gain, history of GDM, family history of diabetes, degree of hyperglycemia, insulin treatment, lipid profiles, and other metabolic factors. Lifestyle interventions, including weight loss, are thought to reduce the risk of postpartum glucose intolerance. Careful attention should be paid to the screening of postpartum glucose intolerance in women with GDM, and concerted efforts should be made to prevent or delay the development of diabetes and other metabolic disorders.
- 28 February 2026
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 41 (1) , 26-33
Open AccessPostpartum Glucose Intolerance in Women with a History of Gestational Diabetes Mellitus: An In-Depth Review
Gestational diabetes mellitus (GDM) is increasing in prevalence worldwide, and postpartum glucose intolerance represents one of the major complications after delivery in women with GDM. A wide range of risk factors for postpartum glucose intolerance have been identified, including ethnicity, genetic predisposition, age, obesity, pre-pregnancy body mass index, gestational weight gain, history of GDM, family history of diabetes, degree of hyperglycemia, insulin treatment, lipid profiles, and other metabolic factors. Lifestyle interventions, including weight loss, are thought to reduce the risk of postpartum glucose intolerance. Careful attention should be paid to the screening of postpartum glucose intolerance in women with GDM, and concerted efforts should be made to prevent or delay the development of diabetes and other metabolic disorders.
- Open Access
- 31 August 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-11
Weight-independent amelioration of adipokine profile by enavogliflozin, a selective SGLT2 inhibitor, in patients with type 2 diabetes
The metabolic benefits of sodium-glucose co-transporter 2 inhibitors in clinical application are well established; however, there is dearth of knowledge on their impact on adipokine regulation. This study investigated the effect of enavogliflozin on adiponectin and leptin in patients with type 2 diabetes. This secondary analysis of a phase III randomized, double-blind, placebo-controlled trial evaluated changes in serum adiponectin and leptin over 24 weeks. Analysis of covariance was used with baseline values and weight change as covariates to examine whether the effects of enavogliflozin persisted after adjusting for weight change. Correlations between adipokine changes and key metabolic parameters were also assessed. Over the 24 weeks, the enavogliflozin group showed increased adiponectin levels with a least squares (LS) mean difference of 0.98 mg/L compared with the placebo group, while leptin levels showed a significant decrease with an LS mean difference of −2.99 µg/L. Enavogliflozin significantly reduced leptin levels over 24 weeks after adjusting for weight change; however, adiponectin changes were not significant after adjusting for weight change. Adiponectin levels significantly increased across weight loss categories, but leptin showed no significant differences. Leptin changes over 24 weeks significantly were positively correlated with changes in homeostasis model assessment of insulin resistance and homeostasis model assessment of β-cell function but significantly negatively correlated with changes in serum ketone and urinary glucose-to-creatinine ratio. Enavogliflozin treatment decreased leptin over 24 weeks in patients with type 2 diabetes, and this effect remained significant after adjusting for weight change, suggesting an improved adipokine profile. Reductions in leptin were also associated with improvements in insulin resistance and increases in serum ketone levels. These results highlight enavogliflozin as a potential treatment beyond glycemic control, offering additional benefits in managing metabolic dysregulation associated with type 2 diabetes. Not applicable (post hoc analysis).
- 31 August 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-11
Open AccessWeight-independent amelioration of adipokine profile by enavogliflozin, a selective SGLT2 inhibitor, in patients with type 2 diabetes
The metabolic benefits of sodium-glucose co-transporter 2 inhibitors in clinical application are well established; however, there is dearth of knowledge on their impact on adipokine regulation. This study investigated the effect of enavogliflozin on adiponectin and leptin in patients with type 2 diabetes. This secondary analysis of a phase III randomized, double-blind, placebo-controlled trial evaluated changes in serum adiponectin and leptin over 24 weeks. Analysis of covariance was used with baseline values and weight change as covariates to examine whether the effects of enavogliflozin persisted after adjusting for weight change. Correlations between adipokine changes and key metabolic parameters were also assessed. Over the 24 weeks, the enavogliflozin group showed increased adiponectin levels with a least squares (LS) mean difference of 0.98 mg/L compared with the placebo group, while leptin levels showed a significant decrease with an LS mean difference of −2.99 µg/L. Enavogliflozin significantly reduced leptin levels over 24 weeks after adjusting for weight change; however, adiponectin changes were not significant after adjusting for weight change. Adiponectin levels significantly increased across weight loss categories, but leptin showed no significant differences. Leptin changes over 24 weeks significantly were positively correlated with changes in homeostasis model assessment of insulin resistance and homeostasis model assessment of β-cell function but significantly negatively correlated with changes in serum ketone and urinary glucose-to-creatinine ratio. Enavogliflozin treatment decreased leptin over 24 weeks in patients with type 2 diabetes, and this effect remained significant after adjusting for weight change, suggesting an improved adipokine profile. Reductions in leptin were also associated with improvements in insulin resistance and increases in serum ketone levels. These results highlight enavogliflozin as a potential treatment beyond glycemic control, offering additional benefits in managing metabolic dysregulation associated with type 2 diabetes. Not applicable (post hoc analysis).
- Open Access
- 30 June 2025
- Published by Korean Diabetes Association in The Journal of Korean Diabetes
- Vol. 26 (2) , 75-79
Diabetes and Sarcopenia
Sarcopenia, defined as the loss of skeletal muscle mass and strength and/or a decrease in physical performance, is generally related to aging. Type 2 diabetes mellitus (T2DM) and sarcopenia are two age-related diseases and have serious effects on the general health and quality of life of those affected. T2DM can cause sarcopenia through the interactions of insulin resistance, inflammation, accumulation of advanced glycation end-products, and oxidative stress. These processes affect muscle mass and strength, protein metabolism, and vascular and mitochondrial dysfunction. Decreased muscle mass in sarcopenia also can play a role in the development of T2DM through the decreased production of myokines that play a role in glucose and fat metabolism. It is important to identify and manage T2DM and sarcopenia in older adults.
- 30 June 2025
- Published by Korean Diabetes Association in The Journal of Korean Diabetes
- Vol. 26 (2) , 75-79
Open AccessDiabetes and Sarcopenia
Sarcopenia, defined as the loss of skeletal muscle mass and strength and/or a decrease in physical performance, is generally related to aging. Type 2 diabetes mellitus (T2DM) and sarcopenia are two age-related diseases and have serious effects on the general health and quality of life of those affected. T2DM can cause sarcopenia through the interactions of insulin resistance, inflammation, accumulation of advanced glycation end-products, and oxidative stress. These processes affect muscle mass and strength, protein metabolism, and vascular and mitochondrial dysfunction. Decreased muscle mass in sarcopenia also can play a role in the development of T2DM through the decreased production of myokines that play a role in glucose and fat metabolism. It is important to identify and manage T2DM and sarcopenia in older adults.
- Open Access
- 1 January 2025
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 49 (1) , 13-21
Big Data Research for Diabetes-Related Diseases Using the Korean National Health Information Database
The Korean National Health Information Database (NHID), which contains nationwide real-world claims data including sociodemographic data, health care utilization data, health screening data, and healthcare provider information, is a powerful resource to test various hypotheses. It is also longitudinal in nature due to the recommended health checkup every 2 years and is appropriate for long-term follow-up study as well as evaluating the relationships between health outcomes and changes in parameters such as lifestyle factors, anthropometric measurements, and laboratory results. However, because these data are not collected for research purposes, precise operational definitions of diseases are required to facilitate big data analysis using the Korean NHID. In this review, we describe the characteristics of the Korean NHID, operational definitions of diseases used for research related to diabetes, and introduce representative research for diabetes-related diseases using the Korean NHID.
- 1 January 2025
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 49 (1) , 13-21
Open AccessBig Data Research for Diabetes-Related Diseases Using the Korean National Health Information Database
The Korean National Health Information Database (NHID), which contains nationwide real-world claims data including sociodemographic data, health care utilization data, health screening data, and healthcare provider information, is a powerful resource to test various hypotheses. It is also longitudinal in nature due to the recommended health checkup every 2 years and is appropriate for long-term follow-up study as well as evaluating the relationships between health outcomes and changes in parameters such as lifestyle factors, anthropometric measurements, and laboratory results. However, because these data are not collected for research purposes, precise operational definitions of diseases are required to facilitate big data analysis using the Korean NHID. In this review, we describe the characteristics of the Korean NHID, operational definitions of diseases used for research related to diabetes, and introduce representative research for diabetes-related diseases using the Korean NHID.
- Open Access
- 30 November 2024
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 48 (6) , 1056-1057
The Importance of Treating Hyperglycemia in β-Cell Dysfunction of Type 2 Diabetes Mellitus
- 30 November 2024
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 48 (6) , 1056-1057
Open AccessThe Importance of Treating Hyperglycemia in β-Cell Dysfunction of Type 2 Diabetes Mellitus